At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 15 enrolled
Drug / intervention
Acthardrug
Likely dose
Acthar 80 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Use of Acthar (ACTH) in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Have Developed Chronic Kidney Disease Stage V (CKD) or End Stage Renal Disease (ESRD) and Are Undergoing a Renal Transplant
In Brief
A Phase 3 clinical trial evaluating Acthar for FSGS. Completed, enrolled 15 participants across 1 site.
Detailed Summary
This study will evaluate the use of Acthar in patients to undergo renal transplantation and will measure the rate of FSGS recurrence.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFSGS
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartFeb 2019
Primary CompletionJun 2024
Study CompletionJun 2024
TodayJul 2026
First PostedFeb 17, 2016
Enrollment StartFeb 1, 2019
Primary CompletionJun 6, 2024
Study CompletionJun 10, 2024
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 10.4 years ago
Interventions
Acthardrug
patients will receive acthar 80 units twice a week for 6 months and will measure recurrence of FSGS